{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:03:57Z","timestamp":1793034237994,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00403-021-02228-9","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T17:02:37Z","timestamp":1618678957000},"page":"275-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Systemic CXCL10 is a predictive biomarker of vitiligo lesional skin infiltration, PUVA, NB-UVB and corticosteroid treatment response and outcome"],"prefix":"10.1007","volume":"314","author":[{"given":"M.","family":"El-Domyati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. H.","family":"El-Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. F.","family":"Rezk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Chervoneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. B.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Farber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Uitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Igoucheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0762-1833","authenticated-orcid":false,"given":"Vitali","family":"Alexeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,17]]},"reference":[{"key":"2228_CR1","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1126\/science.1071545","volume":"296","author":"DS Aaronson","year":"2002","unstructured":"Aaronson DS, Horvath CM (2002) A road map for those who don\u2019t know JAK-STAT. Science 296:1653\u20131655. https:\/\/doi.org\/10.1126\/science.1071545","journal-title":"Science"},{"key":"2228_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/pcmr.12667","volume":"31","author":"M Abdallah","year":"2018","unstructured":"Abdallah M, El-Mofty M, Anbar T, Rasheed H, Esmat S, Al-Tawdy A, Fawzy MM, Abdel-Halim D, Hegazy R, Gawdat H, Bassiouny D, Ibrahim MA, Sany I, El-Bassiouny M, Khalil M, Abdel-Aziz A, El Maadawi ZM, Mostafa WZ (2018) CXCL-10 and Interleukin-6 are reliable serum markers for vitiligo activity: a multicenter cross-sectional study. Pigment Cell Melanoma Res 31:330\u2013336. https:\/\/doi.org\/10.1111\/pcmr.12667","journal-title":"Pigment Cell Melanoma Res"},{"key":"2228_CR3","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.jid.2017.03.020","volume":"137","author":"V Alexeev","year":"2017","unstructured":"Alexeev V (2017) CXCL12 as a predictor of vitiligo activity and disease progression. J Invest Dermatol 137:1588\u20131590. https:\/\/doi.org\/10.1016\/j.jid.2017.03.020","journal-title":"J Invest Dermatol"},{"key":"2228_CR4","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s10103-012-1185-1","volume":"28","author":"AK Alhowaish","year":"2013","unstructured":"Alhowaish AK, Dietrich N, Onder M, Fritz K (2013) Effectiveness of a 308-nm excimer laser in treatment of vitiligo: a review. Lasers Med Sci 28:1035\u20131041. https:\/\/doi.org\/10.1007\/s10103-012-1185-1","journal-title":"Lasers Med Sci"},{"key":"2228_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1600-0781.2006.00222.x","volume":"22","author":"TS Anbar","year":"2006","unstructured":"Anbar TS, Westerhof W, Abdel-Rahman AT, El-Khayyat MA (2006) Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligo affecting different body sites. Photodermatol Photoimmunol Photomed 22:157\u2013163. https:\/\/doi.org\/10.1111\/j.1600-0781.2006.00222.x","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2228_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jid.2017.08.038","volume":"138","author":"K Boniface","year":"2018","unstructured":"Boniface K, Jacquemin C, Darrigade AS, Dessarthe B, Martins C, Boukhedouni N, Vernisse C, Grasseau A, Thiolat D, Rambert J, Lucchese F, Bertolotti A, Ezzedine K, Taieb A, Seneschal J (2018) Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3. J Invest Dermatol 138:355\u2013364. https:\/\/doi.org\/10.1016\/j.jid.2017.08.038","journal-title":"J Invest Dermatol"},{"key":"2228_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/pde.13024","volume":"34","author":"AF de Menezes","year":"2017","unstructured":"de Menezes AF, Oliveira de Carvalho F, Barreto RS, de Santana SB, Shanmugam S, Gurgel RQ, de Souza Araujo AA (2017) Pharmacologic treatment of vitiligo in children and adolescents: a systematic review. Pediatr Dermatol 34:13\u201324. https:\/\/doi.org\/10.1111\/pde.13024","journal-title":"Pediatr Dermatol"},{"key":"2228_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2249.2004.02342.x","volume":"135","author":"F Driessler","year":"2004","unstructured":"Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius AJ (2004) Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol 135:64\u201373. https:\/\/doi.org\/10.1111\/j.1365-2249.2004.02342.x","journal-title":"Clin Exp Immunol"},{"key":"2228_CR9","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.autrev.2017.07.006","volume":"16","author":"SM Ferrari","year":"2017","unstructured":"Ferrari SM, Fallahi P, Santaguida G, Virili C, Ruffilli I, Ragusa F, Centanni M, Antonelli A (2017) Circulating CXCL10 is increased in non-segmental vitiligo, in presence or absence of autoimmune thyroiditis. Autoimmun Rev 16:946\u2013950. https:\/\/doi.org\/10.1016\/j.autrev.2017.07.006","journal-title":"Autoimmun Rev"},{"key":"2228_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/s0190-9622(86)70085-6","volume":"14","author":"RM Halder","year":"1986","unstructured":"Halder RM, Walters CS, Johnson BA, Chakrabarti SG, Kenney JA Jr (1986) Aberrations in T lymphocytes and natural killer cells in vitiligo: a flow cytometric study. J Am Acad Dermatol 14:733\u2013737. https:\/\/doi.org\/10.1016\/s0190-9622(86)70085-6","journal-title":"J Am Acad Dermatol"},{"key":"2228_CR11","doi-asserted-by":"publisher","first-page":"e0121140","DOI":"10.1371\/journal.pone.0121140","volume":"10","author":"MH Jenkins","year":"2015","unstructured":"Jenkins MH, Brinckerhoff CE, Mullins DW (2015) CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity. PLoS ONE 10:e0121140. https:\/\/doi.org\/10.1371\/journal.pone.0121140","journal-title":"PLoS ONE"},{"key":"2228_CR12","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1038\/emm.2016.148","volume":"49","author":"WJ Jin","year":"2017","unstructured":"Jin WJ, Kim B, Kim D, Park Choo HY, Kim HH, Ha H, Lee ZH (2017) NF-kappaB signaling regulates cell-autonomous regulation of CXCL10 in breast cancer 4T1 cells. Exp Mol Med 49:e295. https:\/\/doi.org\/10.1038\/emm.2016.148","journal-title":"Exp Mol Med"},{"key":"2228_CR13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1046\/j.1365-4362.1999.00623.x","volume":"38","author":"SM Kim","year":"1999","unstructured":"Kim SM, Lee HS, Hann SK (1999) The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients. Int J Dermatol 38:546\u2013550. https:\/\/doi.org\/10.1046\/j.1365-4362.1999.00623.x","journal-title":"Int J Dermatol"},{"key":"2228_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13677","author":"RV Kundu","year":"2018","unstructured":"Kundu RV, Mhlaba JM, Rangel SM, Le Poole IC (2018) The convergence theory for vitiligo: a reappraisal. Exp Dermatol. https:\/\/doi.org\/10.1111\/exd.13677","journal-title":"Exp Dermatol"},{"key":"2228_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1749-6632.2009.04813.x","volume":"1173","author":"S Lacotte","year":"2009","unstructured":"Lacotte S, Brun S, Muller S, Dumortier H (2009) CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 1173:310\u2013317. https:\/\/doi.org\/10.1111\/j.1749-6632.2009.04813.x","journal-title":"Ann N Y Acad Sci"},{"key":"2228_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/s1085-5629(97)80030-2","volume":"16","author":"C Le Poole","year":"1997","unstructured":"Le Poole C, Boissy RE (1997) Vitiligo. Semin Cutan Med Surg 16:3\u201314. https:\/\/doi.org\/10.1016\/s1085-5629(97)80030-2","journal-title":"Semin Cutan Med Surg"},{"key":"2228_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.autrev.2008.12.002","volume":"8","author":"EY Lee","year":"2009","unstructured":"Lee EY, Lee ZH, Song YW (2009) CXCL10 and autoimmune diseases. Autoimmun Rev 8:379\u2013383. https:\/\/doi.org\/10.1016\/j.autrev.2008.12.002","journal-title":"Autoimmun Rev"},{"key":"2228_CR18","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1002\/(sici)1521-4141(199811)28:11%3C3696::aid-immu3696%3E3.0.co;2-w","volume":"28","author":"M Loetscher","year":"1998","unstructured":"Loetscher M, Loetscher P, Brass N, Meese E, Moser B (1998) Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 28:3696\u20133705. https:\/\/doi.org\/10.1002\/(sici)1521-4141(199811)28:11%3C3696::aid-immu3696%3E3.0.co;2-w","journal-title":"Eur J Immunol"},{"key":"2228_CR19","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1038\/jid.2009.122","volume":"129","author":"AS Lonsdorf","year":"2009","unstructured":"Lonsdorf AS, Hwang ST, Enk AH (2009) Chemokine receptors in T-cell-mediated diseases of the skin. J Invest Dermatol 129:2552\u20132566. https:\/\/doi.org\/10.1038\/jid.2009.122","journal-title":"J Invest Dermatol"},{"key":"2228_CR20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/315672a0","volume":"315","author":"AD Luster","year":"1985","unstructured":"Luster AD, Unkeless JC, Ravetch JV (1985) Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315:672\u2013676. https:\/\/doi.org\/10.1038\/315672a0","journal-title":"Nature"},{"key":"2228_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1034\/j.1600-0781.2001.170403.x","volume":"17","author":"ME Mofty","year":"2001","unstructured":"Mofty ME, Zaher H, Esmat S, Youssef R, Shahin Z, Bassioni D, Enani GE (2001) PUVA and PUVB in vitiligo\u2013are they equally effective? Photodermatol Photoimmunol Photomed 17:159\u2013163. https:\/\/doi.org\/10.1034\/j.1600-0781.2001.170403.x","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2228_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.12998\/wjcc.v3.i3.221","volume":"3","author":"GF Mohammed","year":"2015","unstructured":"Mohammed GF, Gomaa AH, Al-Dhubaibi MS (2015) Highlights in pathogenesis of vitiligo. World J Clin Cases 3:221\u2013230. https:\/\/doi.org\/10.12998\/wjcc.v3.i3.221","journal-title":"World J Clin Cases"},{"key":"2228_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.det.2016.11.001","volume":"35","author":"JJ Nordlund","year":"2017","unstructured":"Nordlund JJ (2017) The Medical Treatment of Vitiligo: An Historical Review. Dermatol Clin 35:107\u2013116. https:\/\/doi.org\/10.1016\/j.det.2016.11.001","journal-title":"Dermatol Clin"},{"key":"2228_CR24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1524-4725.2011.02234.x","volume":"38","author":"NS Patel","year":"2012","unstructured":"Patel NS, Paghdal KV, Cohen GF (2012) Advanced treatment modalities for vitiligo. Dermatol Surg 38:381\u2013391. https:\/\/doi.org\/10.1111\/j.1524-4725.2011.02234.x","journal-title":"Dermatol Surg"},{"key":"2228_CR25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1089\/jir.2011.0028","volume":"31","author":"LM Pfeffer","year":"2011","unstructured":"Pfeffer LM (2011) The role of nuclear factor kappaB in the interferon response. J Interferon Cytokine Res 31:553\u2013559. https:\/\/doi.org\/10.1089\/jir.2011.0028","journal-title":"J Interferon Cytokine Res"},{"key":"2228_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1365-2133.2009.09091.x","volume":"161","author":"MA Radtke","year":"2009","unstructured":"Radtke MA, Schafer I, Gajur A, Langenbruch A, Augustin M (2009) Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol 161:134\u2013139. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09091.x","journal-title":"Br J Dermatol"},{"key":"2228_CR27","doi-asserted-by":"publisher","first-page":"223ra223","DOI":"10.1126\/scitranslmed.3007811","volume":"6","author":"M Rashighi","year":"2014","unstructured":"Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su MW, Zhou Y, Deng A, Hunter CA, Luster AD, Harris JE (2014) CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med 6:223ra223. https:\/\/doi.org\/10.1126\/scitranslmed.3007811","journal-title":"Sci Transl Med"},{"key":"2228_CR28","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.jid.2016.12.028","volume":"137","author":"AF Rezk","year":"2017","unstructured":"Rezk AF, Kemp DM, El-Domyati M, El-Din WH, Lee JB, Uitto J, Igoucheva O, Alexeev V (2017) Misbalanced CXCL12 and CCL5 chemotactic signals in vitiligo onset and progression. J Invest Dermatol 137:1126\u20131134. https:\/\/doi.org\/10.1016\/j.jid.2016.12.028","journal-title":"J Invest Dermatol"},{"key":"2228_CR29","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.jid.2017.02.012","volume":"137","author":"R Speeckaert","year":"2017","unstructured":"Speeckaert R, Ongenae K, van Geel N (2017) Alterations of CXCL12 in serum of patients with vitiligo. J Invest Dermatol 137:1586\u20131588. https:\/\/doi.org\/10.1016\/j.jid.2017.02.012","journal-title":"J Invest Dermatol"},{"issue":"847\u2013855","key":"2228_CR30","doi-asserted-by":"publisher","first-page":"e845","DOI":"10.1016\/j.jaad.2016.12.021","volume":"76","author":"JP Strassner","year":"2017","unstructured":"Strassner JP, Rashighi M, Ahmed Refat M, Richmond JM, Harris JE (2017) Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J Am Acad Dermatol 76(847\u2013855):e845. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.021","journal-title":"J Am Acad Dermatol"},{"key":"2228_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cca.2013.05.005","volume":"424","author":"MK Tembhre","year":"2013","unstructured":"Tembhre MK, Sharma VK, Sharma A, Chattopadhyay P, Gupta S (2013) T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo. Int J Clin Chem 424:27\u201332. https:\/\/doi.org\/10.1016\/j.cca.2013.05.005","journal-title":"Int J Clin Chem"},{"key":"2228_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1021\/pr800545q","volume":"8","author":"MK Tuck","year":"2009","unstructured":"Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE (2009) Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res 8:113\u2013117. https:\/\/doi.org\/10.1021\/pr800545q","journal-title":"J Proteome Res"},{"key":"2228_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cytogfr.2014.11.009","volume":"26","author":"K Van Raemdonck","year":"2015","unstructured":"Van Raemdonck K, Van den Steen PE, Liekens S, Van Damme J, Struyf S (2015) CXCR3 ligands in disease and therapy. Cytokine Growth Factor Rev 26:311\u2013327. https:\/\/doi.org\/10.1016\/j.cytogfr.2014.11.009","journal-title":"Cytokine Growth Factor Rev"},{"key":"2228_CR34","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/bjd.14416","volume":"174","author":"XX Wang","year":"2016","unstructured":"Wang XX, Wang QQ, Wu JQ, Jiang M, Chen L, Zhang CF, Xiang LH (2016) Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br J Dermatol 174:1318\u20131326. https:\/\/doi.org\/10.1111\/bjd.14416","journal-title":"Br J Dermatol"},{"key":"2228_CR35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2340\/00015555-0194","volume":"87","author":"J Wenzel","year":"2007","unstructured":"Wenzel J, Wiechert A, Merkel C, Bieber T, Tuting T (2007) IP10\/CXCL10 - CXCR3 interaction: a potential self-recruiting mechanism for cytotoxic lymphocytes in lichen sclerosus et atrophicus. Acta Derm Venereol 87:112\u2013117. https:\/\/doi.org\/10.2340\/00015555-0194","journal-title":"Acta Derm Venereol"},{"key":"2228_CR36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3109\/09546634.2014.952610","volume":"26","author":"BH Xiao","year":"2015","unstructured":"Xiao BH, Wu Y, Sun Y, Chen HD, Gao XH (2015) Treatment of vitiligo with NB-UVB: a systematic review. J Dermatolog Treat 26:340\u2013346. https:\/\/doi.org\/10.3109\/09546634.2014.952610","journal-title":"J Dermatolog Treat"},{"key":"2228_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1172\/jci11914","volume":"107","author":"Y Yamamoto","year":"2001","unstructured":"Yamamoto Y, Gaynor RB (2001) Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Investig 107:135\u2013142. https:\/\/doi.org\/10.1172\/jci11914","journal-title":"J Clin Investig"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-021-02228-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-021-02228-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-021-02228-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T12:04:55Z","timestamp":1647086695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-021-02228-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,17]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2228"],"URL":"https:\/\/doi.org\/10.1007\/s00403-021-02228-9","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,17]]},"assertion":[{"value":"23 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}